Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Cobimetinib + Vemurafenib in BRAFv600+ Melanoma
NCT02908672Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2017
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Atezolizumab + Cobimetinib + Vemurafenib with Placebo + Cobimetinib + Vemurafenib (2 arms). Primary endpoint: Progression-Free Survival at 33 months. Started Jan 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02908672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908672.